Hepatocellular carcinoma — a setting for neoantigen vaccines layered onto checkpoint-inhibitor backbones.
[COMPLETED · PHASE1 · Chinese PLA General Hospital] This is a single-center, open-label, non-randomized, parallel-group phase 1 study evaluating a personalized neoantigen-based dendritic cell vaccine following microwave ablation in patients with hepatocellular carcinoma. After re…
Background: The rising burden of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma (HCC) underscores the need for innovative therapeutic strategies. Methods: We integrated RNA-seq fusion detection, immunopeptidomics, and proteoge…
[RECRUITING · PHASE2 · Geneos Therapeutics] This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on p…
Geneos Therapeutics has launched a randomized, open-label Phase II study (NCT07722741) for GNOS-PV02, a personalized neoantigen DNA vaccine combined with plasmid-encoded IL-12 (INO-9012). The trial targets patients with high-risk hepatocellular carcinoma (HCC) who are disease-free post-resection, aiming to prevent recurrence. This marks a significant clinical step for Geneos in validating its DNA-based platform in a adjuvant setting.
Scientists developed a carrier-free nanovaccine for hepatocellular carcinoma by self-assembling fluorinated CpG with HCC neoantigen peptides. The resulting 69 nm nanoparticles demonstrated high loading efficiency and enhanced dendritic cell uptake, improving antigen cross-presentation by 2.05-fold in vitro. In vivo, the formulation targeted lymph nodes to orchestrate both innate and adaptive immune responses, offering a biosafe alternative to traditional adjuvant-loaded nanovaccines.
Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.